St Vincent's Hospital Thoracic Medicine and Cancer Services, Kinghorn Cancer Centre, Australia; St Vincent's Clinical School, UNSW, Australia; Faculty of Medicine, University of Sydney, Australia.
Cancer Council NSW, Cancer Research Division University of Sydney, Sydney Health Partners, Office of the Pro-Vice Chancellor, Research in association with Charles Perkins Centre, University of Sydney, Faculty of Science, School of Psychology, Australia.
Lung Cancer. 2018 Oct;124:199-204. doi: 10.1016/j.lungcan.2018.07.032. Epub 2018 Jul 23.
Multidisciplinary team (MDT) presentation in lung cancer has the potential to improve longterm outcomes, although this varies between studies. This study aims to evaluate outcomes including survival, according to MDT presentation and to explore the utility of data obtained from local clinical sources.
Prospective cases of lung cancer recorded in our institution's cancer registry were analyzed according to MDT presentation for patient and tumour characteristics, adjusted survival and referral to palliative care.
1197 cases were included, 295 (24.6%) with MDT presentation and 902 (75.4%) without. 60% of patients were male with median (IQR) age at diagnosis of 70 years (62-78). Histopathology distribution (non-small cell lung cancer and small-cell lung cancer) was similar between the two groups. Compared with the non-MDT group, the MDT group had (1) ECOG score recorded more often (71.9% vs. 47.6%), (2) higher proportion of ECOG 0 cases (31.2% vs. 11.9%) and ECOG 1 cases (28.8% vs. 20.3%), (3) higher proportion of early stage disease (stage I - 23.1% vs. 9.7% stage II - 10.2% vs. 4.8%, stage IIIA - 14.6% vs 6.3%) and (4) lower proportion of metastatic disease (stage IV - 39.3% vs. 56.1%). Referral to palliative care was incompletely recorded in both groups (MDT: n = 116/295, 39.3%; non-MDT: n = 430, 47.7%) but did not differ significantly for stage IV cases. Survival analyzed by stage was greater in the MDT group at 1, 2 and 5 years for all stages except stage IIIB at 1 year post-diagnosis. Adjusted survival analysis for the entire cohort showed improved survival at 5 years for the MDT group (HR 0.7 (0.58-0.85), p < 0.001).
MDT presentation is associated with improved adjusted survival for lung cancer in this single institutional cohort in an analysis of local clinical cancer registry data.
多学科团队(MDT)在肺癌治疗中具有改善长期预后的潜力,但不同研究结果存在差异。本研究旨在评估生存等结果,依据 MDT 治疗方案,并探索从本地临床资源中获得的数据的实用性。
对我院癌症登记处记录的前瞻性肺癌病例,依据 MDT 治疗方案和患者及肿瘤特征、调整后的生存时间和姑息治疗转诊情况进行分析。
共纳入 1197 例患者,295 例(24.6%)接受了 MDT 治疗,902 例(75.4%)未接受 MDT 治疗。60%的患者为男性,中位(IQR)年龄为 70 岁(62-78 岁)。两组间组织病理学分布(非小细胞肺癌和小细胞肺癌)相似。与非 MDT 组相比,MDT 组(1)更常记录 ECOG 评分(71.9% vs. 47.6%),(2)ECOG 0 评分病例比例较高(31.2% vs. 11.9%)和 ECOG 1 评分病例比例较高(28.8% vs. 20.3%),(3)早期疾病比例较高(I 期-23.1% vs. II 期-10.2%,III 期 A-14.6% vs. 6.3%),(4)转移性疾病比例较低(IV 期-39.3% vs. 56.1%)。两组姑息治疗转诊记录均不完整(MDT:n=295/295,39.3%;非 MDT:n=902,47.7%),但 IV 期病例转诊无显著差异。按分期分析的生存情况显示,MDT 组在所有分期中,1、2 和 5 年的生存率均高于非 MDT 组,但在 1 年时 IIIB 期除外。对整个队列进行调整后的生存分析显示,MDT 组 5 年生存率提高(HR 0.7(0.58-0.85),p<0.001)。
在本机构单队列的本地临床癌症登记数据分析中,MDT 治疗方案与肺癌调整后生存率的提高相关。